|

CDK4/6 inhibitor Clinical Trials

6 actively recruiting trials

Also known as: Abemaciclib / Ribociclib / Palbociclib

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Wenjin Yin2
  • Fudan University2
  • Royal Marsden NHS Foundation Trust1
  • RenJi Hospital1

Indications

  • Breast Cancer6
  • Cancer6
  • Advanced Breast Cancer3
  • ER+ Breast Cancer1
  • Metastatic Breast Cancer1

Other6 trials

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Phase 2
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Phase 3
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Phase 2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.